About Synosia Therapeutics
Synosia Therapeutics is a company based in Basel (Switzerland) founded in 2005 was acquired by Biotie in January 2011. Synosia Therapeutics has raised $91.16 million across 3 funding rounds from investors including UCB, Schroders and Investor. Synosia Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Basel, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Synosia Therapeutics
Synosia Therapeutics has successfully raised a total of $91.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synosia Therapeutics
Synosia Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include UCB, Schroders and Investor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Investments are directed by the Wallenberg family into Nordic sectors.
|
Locked | Locked | Locked |
Investor details for Synosia Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synosia Therapeutics
Investment portfolio details for Synosia Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Synosia Therapeutics
Detailed financials for Synosia Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synosia Therapeutics Comparisons
Peer comparison for Synosia Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synosia Therapeutics
Synosia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of Synosia Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synosia Therapeutics
Complete news archive for Synosia Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synosia Therapeutics
Synosia Therapeutics was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Synosia Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Synosia Therapeutics is a funded company, having raised a total of $91.16M across 3 funding rounds to date.
Synosia Therapeutics was established in 2005 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing pharmaceutical candidates for central nervous system disorders. The lead product, SYN-115, an adenosine A2a antagonist, is advanced for Parkinsons disease treatment. Additional candidates are pursued for Alzheimers disease, bipolar disorder, drug dependence, and post-traumatic stress disorder, with operations centered on research and clinical development.
Synosia Therapeutics's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Synosia Therapeutics has 9 investors. Key investors include UCB, Schroders, Investor, Abingworth, and Biotie.